Real-World Response to Pegcetacoplan in C3 Glomerulopathy: A Two-Case Report (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0707; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Despite treatment with prednisone and mycophenolate mofetil (MMF), Cr worsened to 2.4 mg/dL, and UPCR increased to 2.0 g/g. These 2 cases suggest potential benefit of pegcetacoplan in biopsy-proven C3G, especially in patients with persistent proteinuria or worsening kidney function despite conventional immunosuppressive therapy. Given the limited real-world experience with pegcetacoplan in C3GN, these cases add to the emerging evidence supporting complement-targeted therapy in this difficult-to-treat disease."
Case report • Clinical • Real-world • Real-world evidence • Asthma • Complement-mediated Rare Disorders • Glomerulonephritis • Immunology • Nephrology • Rare Diseases • Renal Disease • Respiratory Diseases
|
|
Sanjeev Gupta; Amol Mittal; Aromma Kapoor; Savneek S. Chugh
|